



FOR RELEASE

Embargoed Until May 20, 9:15 a.m. CT

FOR MORE INFORMATION, CONTACT:

Dacia Morris

dmorris@thoracic.org

ATS Office 212-315-8620 (until May 16)

Session: B21 Severe Asthma: Clinical and Mechanistic Studies

Abstract Presentation Time: Monday, May 20, 9:15 a.m. CT

Location: Room D222-D224 (Level 2), Kay Bailey Hutchison Convention Center
Dallas

LONG-TERM USE OF BENRALIZUMAB APPEARS SAFE, EFFECTIVE FOR SEVERE ASTHMA

ATS 2019, Dallas, TX – Patients with severe eosinophilic [asthma](#), who participated in three different Phase 3 trials of benralizumab (brand name Fasenra) and then enrolled in a long-term trial of the drug's efficacy and safety, continued to experience fewer exacerbations and improved pulmonary function and quality of life, according to research presented at ATS 2019. The continuation study, named BORA, found that the risk of infection did not increase over time and that long-term treatment with benralizumab was well tolerated and did not lead to new safety concerns.

[VIEW ABSTRACT](#)

CONTACT FOR MEDIA

J. Mark FitzGerald

mark.fitzgerald@vch.ca